CD34 and neoplasm: In addition, CD34+ bone marrow (BM) cells were collected at diagnosis in four of the twelve patients, while in three additional patients, sequencing analyses were performed either on mobilized CD34− cells (i.e., CHIP#1) or BM mononuclear cells (MNCs) collected during lenalidomide maintenance therapy (i.e., CHIP#11) or BM-CD138 negative cells (i.e., BM depleted by tumor cells) collected at relapse (i.e., CHIP#1) (as summarized in Figure 1A).